Acarix today announced a rights issue of SEK ~56 million, with guarantee undertakings of SEK ~50.4 million (~90% of the rights issue). In the press release, we learn that the net proceeds will primarily be used for 1) market expansion in Europe 2) FDA approval and establishment on the US market 3) clinical studies 4) further product development of the CADScor system. As Redeye is acting as Financial Advisor to Acarix in connection with the company’s share issue, we present no research views on the valuation nor will we make any estimate changes during the period of the issue, in line with general practice.